Mallinckrodt's MNK-155 shows efficacy in Ph III acute pain trial

US drugmaker Mallinckrodt (NYSE:MNK) reported that a Phase III efficacy trial of investigational MNK-155 met the study’s primary endpoint of improved pain scores versus placebo over the first 48 hours following bunionectomy (p<0.001).

This difference in pain scores was statistically significant in favor of MNK-155. The data is being presented at PAINWeek 2014, a national conference on pain for frontline practitioners, held in Las Vegas, Nevada, USA, September 2-6, 2014.

Uses Depomed’s advanced Acuform drug delivery technology